Tuesday, February 17, 2026 2/17/2026

Prostate-cancer Imaging by Combined Ultrasound and Magnetic-resonance Parameters

Award Number: R01CA140772
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/09/2010
PERIOD OF PERFORMANCE END DATE: 06/30/2016

Group Awards By:

View Award Description

Prostate-cancer Imaging by Combined Ultrasound and Magnetic-resonance Parameters - DESCRIPTION (provided by applicant): Riverside Research Institute, Beth Israel Deaconess Medical Center, Rutgers University, and the General Electric Corporation propose to undertake an Academic-Industrial Partnership study to improve prostate- cancer (PCA) imaging markedly and thereby improve prostate-biopsy guidance to detect PCa; enhance monitoring, surveillance, and treatment of PCa; and enable planning and execution of focal PCa therapy. The project is highly significant because it addresses a major health problem in the United States and other developed countries. The project will overcome the current inability of established clinical-imaging method to image PCa reliably by combining the capabilities of advanced ultrasound (US) and magnetic-resonance (MR) techniques in a clinically effective manner. The proposed approach will exploit the sensitivity of US to mechanical properties of tissue on a microscopic scale with the sensitivity of MR to chemical constituents of tissue and its ability to sense blood distribution. Each of these modalities senses different and independent properties of tissue and has shown encouraging potential for improved imaging of PCa when used alone; combining parameters derived from each modality can provide far superior sensitivity and specificity for PCa. We will combine US and MR parameters using advanced classifiers such as artificial neural networks and support-vector machines. These classifiers already have produced ROC-curve areas of 0.91 for advanced US methods, and the MR methods have demonstrated equivalent ROC-curve areas in many studies. We will embody the combined capabilities in specifications for a prototype imaging system that can generate prostate tissue-typing images (TTIs) in real-time for targeting biopsies or planning treatment in the operating room or in an off-line setting. The latest Logiq E9 instrument currently being produced by GE already has a capability for fusing previously obtained MR images with US images in real time, which provides an existing framework for combining US and MR parameters and generating real-time TTIs. Successfully generating reliable prostate TTIs based on combined US and MR parameters will represent a quantum advance in PCa management by enabling significant improvements in the diagnosis and treatment of PCa.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2017 ( Subtotal = $0 )
2017	2014	RIVERSIDE RESEARCH INSTITUTE	156 WILLIAM ST 9TH FL	NEW YORK	NY	10038	NEW YORK	USA	Cancer Detection and Diagnosis Research	000	5	12/22/2016	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2014 ( Subtotal = $553,498 )
2014	2014	RIVERSIDE RESEARCH INSTITUTE	156 WILLIAM STREET, NINTH FL	MANHATTAN	NY	10038	NEW YORK	USA	Cancer Detection and Diagnosis Research	000	5	7/1/2014	NON-COMPETING CONTINUATION	$553,498
														Subtotal = $553,498

Issue Date FY: 2013 ( Subtotal = $525,013 )
2013	2013	RIVERSIDE RESEARCH INSTITUTE	156 WILLIAM STREET, NINTH FL	MANHATTAN	NY	10038	NEW YORK	USA	Cancer Detection and Diagnosis Research	000	4	6/11/2013	NON-COMPETING CONTINUATION	$525,013
														Subtotal = $525,013

Issue Date FY: 2012 ( Subtotal = $582,054 )
2012	2012	RIVERSIDE RESEARCH INSTITUTE	156 WILLIAM STREET, NINTH FL	MANHATTAN	NY	10038	NEW YORK	USA	Cancer Detection and Diagnosis Research	000	3	6/1/2012	NON-COMPETING CONTINUATION	$582,054
														Subtotal = $582,054

Issue Date FY: 2011 ( Subtotal = $639,137 )
2011	2011	RIVERSIDE RESEARCH INSTITUTE	156 WILLIAM STREET, NINTH FL	MANHATTAN	NY	10038	NEW YORK	USA	Cancer Detection and Diagnosis Research	000	2	6/30/2011	NON-COMPETING CONTINUATION	$639,137
														Subtotal = $639,137

Issue Date FY: 2010 ( Subtotal = $723,266 )
2010	2010	RIVERSIDE RESEARCH INSTITUTE	156 WILLIAM STREET, NINTH FL	MANHATTAN	NY	10038	NEW YORK	USA	Cancer Detection and Diagnosis Research	000	1	8/9/2010	NEW	$723,266
														Subtotal = $723,266

Grand Total All Awards = $3,022,968

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Prostate-cancer Imaging by Combined Ultrasound and Magnetic-resonance Parameters

Award Number: R01CA140772

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/09/2010

PERIOD OF PERFORMANCE END DATE: 06/30/2016

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer